FDA Determines Regulatory Review Period for IMPELLA 2.5 SYSTEM Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of the IMPELLA 2.5 SYSTEM medical device, as required by law, following a submission to the U.S. Patent and Trademark Office (USPTO)